These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 18674639)

  • 1. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway.
    Mellado B; Codony J; Ribal MJ; Visa L; Gascón P
    Clin Transl Oncol; 2009 Jan; 11(1):5-10. PubMed ID: 19155198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding hormonal therapy resistant prostate cancer.
    Donkena KV; Yuan H; Young CY
    Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the androgen receptor in prostate cancer.
    Culig Z
    Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
    Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.
    Eichholz A; Ferraldeschi R; Attard G; de Bono JS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):68-75. PubMed ID: 21986558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond androgen deprivation: ancillary integrative strategies for targeting the androgen receptor addiction of prostate cancer.
    McCarty MF; Hejazi J; Rastmanesh R
    Integr Cancer Ther; 2014 Sep; 13(5):386-95. PubMed ID: 24867960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
    Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
    Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer.
    Uemura M; Honma S; Chung S; Takata R; Furihata M; Nishimura K; Nonomura N; Nasu Y; Miki T; Shuin T; Fujioka T; Okuyama A; Nakamura Y; Nakagawa H
    Cancer Sci; 2010 Aug; 101(8):1897-904. PubMed ID: 20560974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.